Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Molecular pathology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Molecular pathology is an emerging discipline within pathology which is focused in the study and diagnosis of disease through the examination of molecules within organs, tissues or bodily fluids. Molecular pathology shares some aspects of practice with both anatomic pathology and clinical pathology, molecular biology, biochemistry, proteomics and genetics, and is sometimes considered a "crossover" discipline. It is multi-disciplinary in nature and focuses mainly on the sub-microscopic aspects of disease. A key consideration is that more accurate diagnosis is possible when the diagnosis is based on both the morphologic changes in tissues (traditional anatomic pathology) and on molecular testing.
Automated molecular pathology apparatus having fixed slide platforms
ActiveUS7378055B2Analysis using chemical indicatorsWithdrawing sample devicesTissue sampleFixed position
Apparatus and methods for automatically staining or treating multiple tissue samples mounted on slides are provided, in which the slides and reagent bottles are held in fixed position, and the reagent, wash and coverslipping solutions brought to the slides. Alternatively, the slides are held in fixed position, while the reagent, wash and coverslipping solutions brought to the slides.
Owner:VENTANA MEDICAL SYST INC
Automated molecular pathology apparatus having fixed slide platforms
Owner:VENTANA MEDICAL SYST INC
Methods, Reagents, Devices and Instrumentation For Preparing Impregnated Tissue Samples Suitable For Histopathological and Molecular Studies
ActiveUS20080206807A1Low melting pointBioreactor/fermenter combinationsBiological substance pretreatmentsMolecular analysisPathology diagnosis
A process for the production of paraffin sections of biological tissue, especially for molecular pathology studies is disclosed. In the process, the tissue sample is simultaneously fixed, dehydrated and cleared in a first step, subsequently dehydrated and cleared in a second step and infiltrated with an inert specimen matrix in a third step. The specimen can then be further embedded in a casting supporting matrix according to the standard procedures followed by any local pathology or research laboratory. A kit and a processing station for automating paraffin embedding of a tissue sample suitable for histopathological and molecular analysis is also described. A bio-indicator system is described for measuring the degree of crosslinking. A tissue sample holding means or a vial which includes a tissue sample holding means provided with a data logging device capable of registering and transmitting data regarding the sample and conditions where the sample was processed is also disclosed.
Owner:CELLCARTA NV
Closed loop monitoring of automated molecular pathology system
ActiveUS20120135458A1Bioreactor/fermenter combinationsBiological substance pretreatmentsStainingClosed loop
A closed loop automated method for staining of a biological sample is provided. The method comprises providing a biological sample, staining at least a portion of the biological sample by flowing in a reagent, monitoring one or more optical characteristics of the biological sample, and calculating a figure of merit based on at least one of the optical characteristics. An automated device for iterative staining of a biological sample is also provided.
Owner:LEICA MICROSYSTEMS CMS GMBH
Methods, Reagents and Instrumentation for Preparing Impregnated Tissue Samples Suitable for Histopathological and Molecular Studies
InactiveUS20080274496A1Preparing sample for investigationLaboratory glasswaresPathology diagnosisStandard procedure
A process and kit for the production of paraffin sections of biological tissue, especially for molecular pathology studies, is described. In the process, the tissue sample is simultaneously fixed, dehydrated and cleared in a first step, subsequently dehydrated and cleared in a second step and infiltrated with an inert specimen matrix in a third step. The specimen can then be further embedded in a casting supporting matrix according to the standard procedures followed by any local pathology or research laboratory. The method is uncomplicated, requires little hands-on time, is reproducible and is standardized thereby limiting cross-centre pre-analytical variance. A bio-indicator system for measuring the degree of crosslinking is also disclosed.
Owner:HISTOGENEX NV
Automated molecular pathology apparatus having fixed slide platforms
InactiveUS20070086917A1Preparing sample for investigationMaterial analysis by optical meansTissue sampleFixed position
Apparatus and methods for automatically staining or treating multiple tissue samples mounted on slides are provided, in which the slides and reagent bottles are held in fixed position, and the reagent, wash and coverslipping solutions brought to the slides. Alternatively, the slides are held in fixed position, while the reagent, wash and coverslipping solutions brought to the slides.
Owner:VENTANA MEDICAL SYST INC
Formaldehyde-free fixative for tissue sample
InactiveCN102175496AAvoid toxic effectsRemove coverPreparing sample for investigationSurface-active agentsBiology
The invention provides a formaldehyde-free fixative for a tissue sample, which comprises the following ingredients in parts by volume: 710-790 parts of ethanol, 20-40 parts of glacial acetic acid, 10-30 parts of acetone, 40-60 parts of polyhydric alcohol, 40-60 parts of trichloroacetic acid (TDA), 40-60 parts of surface active agent and 40-60 parts of solubilizing agent. The formaldehyde-free fixative is a nontoxic and innocuous chemical reagent; after being proved by cellular morphological experiments, immunohistochemical experiments, molecular pathological experiments and nucleic acid extraction experiments, the formaldehyde-free fixative has relatively comprehensive fixing effect, can replace the formaldehyde and be used in related pathological experiments, thereby fixing the tissue sample.
Owner:HARBIN GREEN SPECIMEN TECH DEV
Method for rapidly concentrating and extracting nucleic acid target cells from sample
InactiveCN103224929AIncrease nucleic acid concentrationImprove the positive rate of pathological detectionDNA preparationBiologyDimethyl benzene
The present invention discloses a method for rapidly concentrating and extracting nucleic acid target cells from a sample, wherein the method comprises the steps of fixing surgical or biopsy specimens with neutral formalin, dehydrating to be embedded in paraffin, cutting multiple white slices and selecting one for HE staining, observing tumor tissue cell distribution of HE stained slices under an optical microscope, and marking the distribution area of target cells; baking the remained white slices for xylene dewaxing, scraping the tissue rich in target cells on the white slices according to the marked HE stained slices for target cells concentrating, and extracting nucleic acid from the concentrated target cells. The method can improve concentration of nucleic acid in the target cells to up to more than 40% to 60% so as to raise positive rate of molecular pathology detection and reduce false negative rate without any expensive equipment or specialized complex technology with almost no obvious time consumption, therefore the method is suitable for being applied in all inspection department of pathology and biological laboratories and is used to provide more accurate molecular diagnosis for clinical diagnosis and treatment.
Owner:南京紫霄科技有限公司 +2
Closed loop monitoring of automated molecular pathology system
ActiveUS8673643B2Bioreactor/fermenter combinationsBiological substance pretreatmentsStainingClosed loop
Owner:LEICA MICROSYSTEMS CMS GMBH
Construction method of recombinant plasmid of PD-L1 (programmed death-ligand 1) in chicken peripheral blood mononuclear lymphocytes, real-time gene abundance detection method and application of detection method
ActiveCN103789335AIncreased sensitivityGood linear relationshipMicrobiological testing/measurementVector-based foreign material introductionSequence analysisTotal rna
The invention belongs to the technical field of molecular pathology and immunology and in particular relates to a construction method of recombinant plasmid of PD-L1 (programmed death-ligand 1) in chicken peripheral blood mononuclear lymphocytes, a real-time gene abundance detection method and application of the detection method. The construction and detection methods comprise the following steps: acquiring total RNA (ribonucleic acid) of chicken lymphocytes and carrying out reverse transcription on the total RNA to obtain cDNA (complementary deoxyribonucleic acid); carrying out common PCR (polymerase chain reaction) amplification on a PD-L1 target gene segment, detecting the target gene segment through agarose gel electrophoresis and recovering and purifying the target gene segment; connecting the PD-L1 target gene segment with a pMD18-T carrier, transforming the product into a competent cell DH5alpha and extracting the recombinant plasmid; carrying out sequencing analysis after cloning and screening, selecting positive plasmid with the same sequence as the target gene segment as standard plasmid and drawing a standard curve according to the copy concentration; and detecting the gene abundance of the PD-L1 according to fluorescence signal change and the standard curve. The real-time PD-L1 gene abundance detection method has the advantages of high detection flux, high sensitivity, strong specificity, simplicity and convenience in operation, low cost, accuracy in quantification and the like.
Owner:XINXIANG UNIV
Formaldehyde-free fixative for tissue sample
InactiveCN102175496BAvoid toxic effectsRemove coverPreparing sample for investigationSurface-active agentsBiology
Owner:HARBIN GREEN SPECIMEN TECH DEV
Construction of pig peripheral bloodmononuclear lymphocytePD-1 (programmed death-1) recombinantplasmids, real-time gene abundance detection method and application of method
ActiveCN103966314AMicrobiological testing/measurementVector-based foreign material introductionSequence analysisProgrammed death
The invention belongs to the technical field ofmolecular pathology andimmunology, and relates to construction of pig peripheral bloodmononuclear lymphocytePD-1 (programmed death-1) recombinantplasmids, a real-time gene abundance detection method and an application of the method. TotalRNA of pig peripheral bloodmononuclear lymphocytes is collected and reverselytranscribed into cDNA (complementary DNA); PD-1 target gene fragmentsare amplified through a general PCR (polymerase chain reaction), detected throughagarose gel electrophoresis, recovered and purified; the PD-1 target gene fragments are connected with pMD18-T carriers and converted into competent cells DH5alpha, and the recombinantplasmids are extracted; sequencing analysis is performed after cloning and screening, positive plasmids with the same sequence as the targetgene fragments are selected to serve as standard plasmids, and a standard curve is drawn according to the copy concentration; thePD-1 gene abundance is measured according to fluorescence signal changes and the standard curve. The real-time pig PD-1 gene abundancedetection method has the advantages of high detection throughput, high susceptibility, high specificity, convenience in operation, low cost, accuracy in quantification and the like.
Owner:XINXIANG UNIV
Detection method and chip for susceptibility gene of dilatant and hypertrophic cardiomyopathy
InactiveCN109762879AShort processStrong targetingNucleotide librariesMicrobiological testing/measurementGuidelineHypertrophic cardiomyopathy
The invention relates to a detection method and chip for a susceptibility gene of dilatant and hypertrophic cardiomyopathy. Based on a target region capture high-throughput sequencing technology, a group of specific and effective gene set associated with DCM / HCM cardiovascular disease is selected and is subjected to high-throughput capture and sequencing analysis by a self-developed probe library-building capture process and analysis software, so as to find out variation conditions of genetic level cardiovascular disease-related genes, especially DCM / HCM genes and the like, by gene means to screen the susceptibility gene. The screening result refers to the guidelines of the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP) to interpret variations. Compared with conventional high-throughput sequencing, a kit has the advantages of high pertinence, low cost, fast flow and the like.
Owner:葛均波 +2
Alzheimer disease pathogenic gene and application thereof
InactiveCN102604959AFacilitate clear molecular diagnosisFacilitate molecular typingMicrobiological testing/measurementFermentationDiseaseNucleotide sequencing
The invention discloses an Alzheimer disease (AD) pathogenic gene and an application thereof, which belong to the technical field of molecular pathology. The cDNA nucleotide sequence of the gene is represented by SEQ ID NO:1. The invention also relates to a recombinant vector containing the Alzheimer disease pathogenic gene, a recombinant cell containing the recombinant vector, a coding protein of the Alzheimer disease pathogenic gene, and an exon of the Alzheimer disease pathogenic gene. The detection of the gene with the Alzheimer disease pathogenic gene exon can be used in gene molecular diagnosis of an AD patient, or in determining pathogenic risk prediction of AD patient relatives. The invention assists in providing an important clue for the AD pathogenic mechanism. An exon vector containing the Alzheimer disease pathogenic gene can be used for preparing an AD cell or an animal model.
Owner:BEIJING JIAOTONG UNIV
CDNA in situ hybridization probe of Her-2 gene, and preparation method thereof
ActiveCN104878076AEasy to observeAccurate observationMicrobiological testing/measurementDNA preparationHybridization probeTotal rna
The invention discloses a cDNA in situ hybridization probe of a Her-2 gene, and a preparation method thereof, and belongs to the field of molecular pathology diagnosis. The preparation method of the probe comprises the following steps: collecting breast cancer patient's fresh tumor tissues highly expressing the Her-2 gene, extracting the total RNA of the tumor tissues, carrying out reverse transcription on the total mRNA to form cDNA, carrying out PCR amplification on the cDNA and a primer to obtain an amplification product, and constructing a plasmid containing the cDNA in situ hybridization probe sequence of the Her-2 gene, wherein the amplification product is a Her-2 gene fragment with the length of 987bp and also is the fragment of the probe; and carrying out probe marking with the plasmid as a template by using the primer and a DIG polymerase chain reaction probe synthesis kit to obtain the probe. The cDNA in situ hybridization probe sequence of the Her-2 gene has clear specificity to the DNA of the Her-2 gene, and realizes detection of the DNA amplification condition of the Her-2 gene.
Owner:JIANGHAN UNIVERSITY
Composition and Method for the Treatment of Tauopathies
InactiveUS20070232584A1High degreeConvenient synthetic accessBiocideNervous disorderDepressantTau hyperphosphorylation
The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and / or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
Owner:TAU PHARM LLC
Composition and method for the treatment of tauopathies
InactiveUS8003631B2High degreeConvenient synthetic accessBiocideNervous disorderPick's diseaseFrontal lobe dementia
The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurodegenerative and / or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
Owner:TAU PHARM LLC
Biomarkers for diagnosis and prognosis of corneal ectatic disorders
ActiveUS20180067128A1Cell receptors/surface-antigens/surface-determinantsMicrobiological testing/measurementDiseaseCornea diseases
The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and / or TLR4 markers. The invention also relates to the use of the TLR2 and / or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
Owner:UNIVERSITY OF SANTIAGO DE COMPOSTELA +1
Raman gastroscope diagnostic unit
InactiveCN106923781AReal-time molecular pathology diagnosisNoninvasive Molecular Pathology DiagnosisGastroscopesOesophagoscopesRaman imagingFlexible endoscope
The invention discloses a Raman gastroscope diagnostic unit. The Raman gastroscope diagnostic unit comprises a gastroscope imaging system and a Raman imaging system. The gastroscope imaging system comprises a light source and a flexible endoscope, wherein the flexible endoscope collects the image in the stomach by means of the brightness of the light source. The Raman imaging system can acquire Raman spectra of gastric tissue. During gastroscopy, the gastroscope imaging system acquires the image in the stomach and judges whether there is a suspicious lesion in the stomach according to the image, then the Raman imaging system detects the suspicious lesion, laser light emitted by a laser device is transmitted to a probe through transmission fiber and irradiates on the suspicious lesion to trigger a Raman signal to be sent out, and the probe acquires the Raman signal and transmits the Raman signal to a spectrum analyzer, so that the Raman spectra are obtained. The Raman spectra correspond to molecular structures in an one-to-one mode, molecule-level detection is conducted on the suspicious lesion, and a diagnosis result as to whether corresponding tissue is diseased can be obtained directly. By the adoption of the Raman gastroscope diagnostic unit, real-time, non-invasive and precise molecular pathological diagnosis can be realized during gastroscopy.
Owner:江苏拉曼医疗设备有限公司
Construction method of recombinant plasmid of PD-1 (programmed death-1) in chicken peripheral blood mononuclear lymphocytes, real-time gene abundance detection method and application of detection method
InactiveCN103789432AMechanisms of Enriched ImmunosuppressionMicrobiological testing/measurementVector-based foreign material introductionSequence analysisTotal rna
The invention belongs to the technical field of molecular pathology and immunology and in particular relates to a construction method of recombinant plasmid of PD-1 (programmed death-1) in chicken peripheral blood mononuclear lymphocytes, a real-time gene abundance detection method and application of the detection method. The construction and detection methods comprise the following steps: acquiring total RNA (ribonucleic acid) of chicken lymphocytes and carrying out reverse transcription on the total RNA to obtain cDNA (complementary deoxyribonucleic acid); carrying out common PCR (polymerase chain reaction) amplification on a PD-1 target gene segment, detecting the target gene segment through agarose gel electrophoresis and recovering and purifying the target gene segment; connecting the PD-1 target gene segment with a pMD18-T carrier, transforming the product into a competent cell DH5alpha and extracting the recombinant plasmid; carrying out sequencing analysis after cloning and screening, selecting positive plasmid with the same sequences as the target gene segment as standard plasmid and drawing a standard curve according to the copy concentration; and detecting the gene abundance of the PD-1 according to fluorescence signal change and the standard curve. The real-time PD-1 gene abundance detection method has the advantages of high detection flux, high sensitivity, strong specificity, simplicity and convenience in operation, low cost, accuracy in quantification and the like.
Owner:XINXIANG UNIV
DRD (Dope-Reactive Dystonia)-related gene mutation and detecting method and usage thereof
ActiveCN103725687AMicrobiological testing/measurementFermentationDopa-Responsive DystoniaTyrosine hydroxylase
The invention belongs to the field of molecular pathology and particularly relates to a DRD (Dope-Reactive Dystonia)-related gene mutation, in particular to two mutant types of a DRD-related TH (Tyrosine hydroxylase) gene.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV +1
Kit for extracting DNA from biological tissue sample by paraffin imbedding method and extraction method
The invention discloses a kit for extracting DNA from a biological tissue sample by a paraffin imbedding method. The kit comprises a deparaffinating solvent A, a buffer solution B, protein digestive fluid C, a nucleic acid purification column D and eluate E, wherein the deparaffinating solvent A contains SDS, NP40 and NaCL, and the buffer solution B contains EDTA, NaCL and SDS. According to the kit for extracting the DNA from the biological tissue sample by the paraffin imbedding method, disclosed by the invention, the quality of the extracted DNA fully meets the requirements of molecular pathology detection, and the extracted DNA is high in content.
Owner:上海革亚医疗科技有限公司
Biomarkers for diagnosis and prognosis of corneal ectatic disorders
ActiveUS10914746B2Cell receptors/surface-antigens/surface-determinantsMicrobiological testing/measurementDiseasePrognosis biomarker
Owner:UNIVERSITY OF SANTIAGO DE COMPOSTELA +1
Application of B7H4 in preparation of endometrial cancer molecular typing reagent and system
ActiveCN113156120AImprove survival rateImprove predictive performanceSystems biologyMaterial analysisEndometrial CarcinomasMismatch Repair Protein
The invention relates to application of B7H4 in preparation of an endometrial cancer molecular typing reagent and system. The method comprises the following steps: firstly, screening out a POLE mutant by a sequencing method; detecting four kinds of mismatch repair proteins on a specimen without pathogenic mutation, and screening out a dMMR type; screening out a p53 mutant from a sample without dMMR by means of immunohistochemical detection of p53 protein; if the p53 mutation does not exist, determining that the p53 mutation is an NSMP type; and for specimens for interpreting the dMMR type and the NSMP type, detecting expression of protein B7H4 through immunohistochemistry, wherein B7H4 coloring in more than 1% of tumor cells is judged as a B7H4 expression type, and B7H4 non-expression types are judged in the rest. According to the invention, endometrial cancer is divided into a POLE mutant type, a B7H4 expression type, a B7H4 non-expression type and a p53 mutant type; and the improved molecular typing is still based on molecular pathology, has the characteristics of relative objectiveness, high repeatability and clinical feasibility of the existing molecular typing, but has higher predictive ability than the existing model, and is beneficial to avoiding excessive treatment and insufficient treatment.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Hereditary medullispinal cerebellar ataxia related gene
The invention belongs to the field of molecular pathology, and relates to a hereditary medullispinal cerebellar ataxia related gene (mutant), particularly a hereditary medullispinal cerebellar ataxia related gene of which the amino acid sequence is disclosed as SEQ ID NO:7 or SEQ ID NO:9, and more particularly a hereditary medullispinal cerebellar ataxia related gene of which the nucleic acid sequence is disclosed as SEQ ID NO:6 or SEQ ID NO:8. The invention also relates to a recombinant vector containing the medullispinal cerebellar ataxia related gene, a recombinant cell containing the recombinant vector, and a coding protein of the medullispinal cerebellar ataxia related gene. Besides, the invention also relates to an exon of the hereditary medullispinal cerebellar ataxia related gene and a coding protein thereof. The invention provides references for auxiliary molecular diagnosis, molecular typing, prenatal diagnosis, drug target selection and clinical treatment of the hereditary medullispinal cerebellar ataxia.
Owner:CENT SOUTH UNIV +1
A method for isolating and culturing cells from aged human synovial articular cartilage
ActiveCN110484495BFully contactedIncrease productionCell dissociation methodsSkeletal/connective tissue cellsHuman bodyCell-Extracellular Matrix
Owner:JIANGNAN UNIV
Kit and method for detecting programmed cell death 1 ligand 1 (PD-L1) mRNA on tissue
ActiveCN111378723ASimple compositionMake up for the current situationMicrobiological testing/measurementAgainst vector-borne diseasesAntiendomysial antibodiesFluorescence in situ hybridization
This application belongs to the technical field of biology, and discloses a kit and method for detecting programmed cell death 1 ligand 1 (PD-L1) mRNA on tissue. The kit disclosed by the invention comprises probe sets shown by SEQ ID NO. 1-91. The kit has simple composition, remedies the current situation that immunohistochemical effective antibodies are lacking, eliminates the shortcomings of a fluorescence in situ hybridization (FISH) technology, and greatly expands the field of detection of molecular pathology.
Owner:ZHENGZHOU KODIA BIOTECHNOLOGY CO LTD
DRD (Dope-Reactive Dystonia)-related gene mutation and detecting method and usage thereof
ActiveCN103725687BMicrobiological testing/measurementFermentationDopa-Responsive DystoniaTyrosine hydroxylase
The invention belongs to the field of molecular pathology and particularly relates to a DRD (Dope-Reactive Dystonia)-related gene mutation, in particular to two mutant types of a DRD-related TH (Tyrosine hydroxylase) gene.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV +1
Construction of pd-l1 recombinant plasmid in porcine peripheral blood mononuclear lymphocytes, real-time detection method of gene abundance and its application
ActiveCN103966313BAccurate quantification of transcript levelsMicrobiological testing/measurementVector-based foreign material introductionSequence analysisPD-L1
The invention belongs to the technical field of molecular pathology and immunology, and relates to construction of pig peripheral bloodmononuclear lymphocytePD-L1 (programmed death-ligand1) recombinantplasmids, a real-time gene abundance detection method and an application of the method. TotalRNA of pig peripheral bloodmononuclear lymphocytes is collected and reverselytranscribed into cDNA (complementary DNA); PD-L1 target gene fragments are amplified through a general PCR (polymerase chain reaction), detected throughagarose gel electrophoresis, recovered and purified; the PD-L1 targetgene fragments are connected with pMD18-T carriers and converted into competent cells DH5alpha, and the recombinantplasmids are extracted; sequencing analysis is performed after cloning and screening, positive plasmids with the same sequence as the target gene fragments are selected to serve as standard plasmids, and a standard curve is drawn according to the copy concentration; thePD-L1 gene abundance is measured according to fluorescence signal changes and the standard curve. The real-time pig PD-L1 gene abundancedetection method has the advantages of high detection throughput, high susceptibility, high specificity, convenience inoperation, low cost, accuracy inquantification and the like.
Owner:XINXIANG UNIV
A Specimen Management Device for Molecular Pathology Detection
ActiveCN112938180BRealize fit cleaning effectTo achieve a driving cleaning effectCleaning using toolsContainers preventing decayMedicineElectric machinery
The invention discloses a specimen management device and method for molecular pathology detection, comprising a storage box body, the outer side wall of the storage box body is slidably connected with a box door, and the outer side wall of the box door is fixedly connected with a box door handle, so The side wall of the box door is sleeved with an outer frame of the box door, the side wall of the outer frame of the box door is fixedly connected with the outer side wall of the storage box body, and the side wall of the storage box body is fixedly installed with a dehumidification air duct, and the A motor frame is fixedly installed on the inner side wall of the dehumidifying air duct. Through the cooperation of the uniaxial motor, the driving mechanism, the air pressure mechanism, the fan, the spring and the traction rope, the present invention utilizes the driving effect of the uniaxial motor and the wind effect of the rotation of the fan to realize the dehumidification work of the box door and the storage box. The driving and cleaning effect of the body connection at the same time realizes the cleaning effect of the air outlet net, avoids the accumulation of dust on the air outlet net, improves the dehumidification efficiency of the dehumidifier, and avoids the accumulation and pollution of damp dust at the air outlet.
Owner:THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com